Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
568 Leser
Artikel bewerten:
(2)

Regener Eyes: First-in-Class Biologic Eye Drop Regener-Eyes Launches "Mechanism of Action" Video Series

The new video series educates on the root causes of dry eye disease, and how Regener-Eyes® may provide some relief.

PALM HARBOR, FL / ACCESSWIRE / February 12, 2021 / Regener-Eyes®, a leading first-in-class biologic eye drop made of naturally-occurring cytokines and growth factors, has launched a new "Mechanism of Action" video series.

For those outside of the medical field, a mechanism of action refers to the biochemical process through which a therapeutic agent produces its effect. This effect can include relief and healing of mild, moderate, or severe dry eye symptoms that are potentially brought upon by a myriad of underlying conditions, such as Sjogren's Syndrome, recurrent corneal erosion, keratitis, neuropathic eye pain, and meibomian gland dysfunction.

"We know that many patients who suffer from dry eye disease are looking for clear, reliable information that helps them understand the condition, and learn about the mechanism of action for leading products such as Regener-Eyes®. They may experience improvement, both with respect to symptom relief, and overall long-term healing, repairing and regenerating of the ocular surface," commented C. Randall Harrell, M.D., CEO and Founder of Regener-Eyes®. "Our new video series helps eye care professionals, and their patients get the essential information they need to turn questions into answers and move forward on the physician approved treatment path that is best for them."

Volume 1 in the new series explores the causes of dry eye disease and explains that damage to any of the three structures that compose the eye's tear film - namely the mucous layer (conjunctiva), the aqueous layer (lacrimal gland), or the lipid layer (meibomian gland) - can lead to dry eye disease. In some cases, an individual's own immune system triggers and exacerbates the disease.

"Antigen presenting cells such as macrophages or dendritic cells can confuse these structures as foreign antigens, and train the immune system to eliminate the threat," explains the video's narrator, with accompanying animated sequences. "Once activated, macrophages secrete pro-inflammatory cytokines such as tumor necrosis factor alpha and interleukin-1 beta. These cytokines then bind to designated receptors on the cell surface of the meibomian gland, lacrimal gland, or the corneal epithelium. The bound complexes then act like a signalling beacon, inducing a massive influx of dendritic and other lymphatic cells to the region, which then infiltrate and destroy the labeled cells of meibomian glands and the ocular surface of patients with dry eye disease."

All videos in the new Mechanism of Action series are available on the Regener-Eyes® YouTube Channel, which also features testimonials from patients, and feedback from renowned dry eye experts such as Dr. Marguerite McDonald, MD, FACS and Dr. Paul Karpecki, OD, FAAO.

About Regener-Eyes®

Regener-Eyes® is a sterile biologic eye drop made of anti-inflammatory cytokines and growth factors. These types of proteins have been shown to reduce inflammation and stimulate the ocular surface to heal, repair, and regenerate. If you have patients that are not responding to current dry eye drugs, amniotic membrane intolerant, or having issues with blood serum tears, many physicians are finding success with Regener-Eyes® as a new option. For more information on our first in class biologic eye drop, please visit www.mydryeyes.org, follow us Instagram, like us on Facebook and connect with us on LinkedIn.

Contact Information:

Regener-Eyes®, LLC
Heidi Hart Pukas
heidi.pukas@regenerativeplant.org

SOURCE: Regener Eyes



View source version on accesswire.com:
https://www.accesswire.com/629551/First-in-Class-Biologic-Eye-Drop-Regener-Eyes-Launches-Mechanism-of-Action-Video-Series

© 2021 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.